Interview with Fabian Dwyer, General Manager, IMS Health Australia
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Address: Suite 406, Kew Junction Tower, 89 High Street Kew, Vic 3101,Australia
Tel: +61 3 9455 1444
Web: http://www.imshealth.com.au/
With offices in Sydney, Melbourne and Auckland, IMS Health Australia is a trusted partner delivering solutions to local pharmaceutical and healthcare sectors.
IMS Health Australia captures information from a wide range of sources including pharmacies, hospitals, pharmaceutical wholesales, healthcare professionals, software suppliers and the pharmaceutical industry. This information is combined to give a complete picture of the market and is critical in business decisions such as assessing the impact of product launches or identifying new uses for existing therapies.
IMS Health Australia provides crucial insight into the pharmaceutical industry, healthcare manufacturers, distributors, government and healthcare agencies, academic institutions and research organizations. This information enables the development of medical education and information programs, rationale of the cost-effectiveness of drug therapies and evaluation of patient health outcomes in health policy decisions. This information is critical to both IMS Health Australia’s customers and supply partners and provides a clearer picture of the healthcare landscape.
IMS Health Australia is committed to servicing the information needs of the healthcare sector. IMS Health Australia offers a continuum of capabilities from information to analytics to consulting. With over 50 years experience and offices in more than 100 countries, IMS Health Australia is the leading source of global information for the pharmaceutical and healthcare industry.
Analytics, Research and development, Generics, Consulting
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
See our Cookie Privacy Policy Here
